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Summary Prescribing practices for patients with cancer pain among populations of doctors in the United
Kingdom have been assessed by means of a postal questionnaire. The results indicate that amongst the sample
of doctors completing the questionnaire the basic principles of pain control in cancer appear to be understood.
Regular oral morphine or diamorphine are most often chosen with the dose being determined mainly by the
severity of pain with no arbitrary upper limit. Fears of addiction and respiratory depression, and a relatively
long prognosis no longer appear to be major deterrents to the use of strong opioid analgesics. These data
indicate considerable shifts in opinion in the doctors responding to the questionnaire and these results and
their implications for current and future teaching about the management of cancer pain are discussed.
The management of pain in patients with cancer has changed
considerably in the past 10-20 years. The principles of
regular oral administration of analgesics and individualisa-
tion of dose (Saunders, 1963) have been widely promoted
and increasingly adopted.
Data from hospices and continuing care units in the UK
indicate that pain is a major problem in 75% of patients on
admission. Yet these specialist centres report figures for
unrelieved pain of only 1-10% when the principles of effect-
ive pain management are properly applied (Twycross &
Lack, 1983). This suggests that there remain considerable
problems in successfully achieving control of pain in cancer
patients in non-specialist environments. At the root of this
may be continued misunderstanding of, or inappropriate
fears about, the strong analgesic drugs likely to be needed in
this situation.
A review of medical inpatients with pain from a variety of
causes published in 1973 found that 73% of patients had
poor control of their pain, with 32% of these reporting
severe distress (Marks & Sacher, 1973). A major contributory
factor appeared to be inappropriate and inadequate use of
analgesic medication. The study was based on a question-
naire survey of staff physicians in two large New York
Hospitals and revealed considerable confusion about the use
of strong opioid analgesics. In particular there were exag-
gerated fears of the dangers of addiction and a tendency to
overestimate potency and duration of action.
We have sought to assess prescribing practices for patients
with cancer pain among populations of doctors in the United
Kingdom. A postal questionnaire was used in order to see
whether similar attitudes to those previously reported were
still prevalent.
Subjects and method
Following a pilot study at the Royal Marsden Hospital,
Sutton, in June 1987, the questionnaire was distributed to
every member of the medical staff in four different types of
medical practice in order to try to provide a broad view of
doctors' attitudes. These were a specialist oncology hospital
(The Royal Marsden Hospital, London); an undergraduate
teaching hospital (Manchester Royal Infirmary); a district
general hospital (Basingstoke General Hospital); and General
Practitioners in inner city (Kensington and Chelsea, Isling-
ton, Bloomsbury and Hampstead) and suburban areas
(Hounslow, Middlesex and Elstree, Herts). The names of
individual doctors were obtained from the General Managers
or Directors of Personnel of the hospitals concerned and the
Medical Executive Committees were also informed. In the
case of the general practitioners names were obtained from
the relevant Family Practitioner Committees. The question-
naire was accompanied by an explanatory letter and pre-paid
return envelope. Medical staff from the specialist oncology
hospital received a second questionnaire if they had not
replied within a period of 8 weeks. No reminders were sent to
the remaining three groups.
Data analysis
The questionnaires and method of delivery used in the pilot
study were found to be feasible, hence no alterations were
made before commencing the main study. Data from the
pilot study have been therefore combined with that from the
main study in the analyses presented.
In the analysis the study sample has been divided into
three groups: specialist oncology hospitals (the two Royal
Marsden Hospitals), general hospitals (Manchester Royal
Infirmary and Basingstoke District General Hospitals) and
general practice.
Disparity between the total number of replies and the
totals for individual questions is due to respondents failing to
answer certain questions.
Results
The response rate was 62% (36/58) in the London branch of
the Royal Marsden Hospital and 72% (42/58) in the Sutton
branch, giving a figure of 67% (78/116) when the two are
combined; 33% (95/284) from the teaching hospital; 34%
(34/100) from the district general hospital; and 46% (58/125)
from the General Practitioners. The overall response rate was
42% (265/625).
The composition of the study sample in terms of seniority
is shown in Figure 1. For hospital doctors the grade of their
present post has been used and for GP's the number of years
since qualification.
The drug of first choice for analgesia in the patient with
severe chronic cancer pain is shown in Table I. Morphine
emerges as the most commonly used drug, chosen by 66% of
doctors. A further 14% use diamorphine. MST Continus
(controlled release morphine tablets) was the most popular
preparation, particularly amongst the general practitioners
and with younger doctors, being specified by 61% of those
qualified for less than 5 years compared to 32% of those
qualified for over 20 years.
A total of 49 doctors, including 14 GP's and 14 in surgical
specialities, did not choose morphine or diamorphine. Weak-
er analgesics, either paracetamol, weak opioids (codeine,
dihydrocodeine or dextropropoxyphene in the form of cop-
roxamol) or nonsteroidal anti-inflammatory drugs (NSAIDs)
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Table I First choice analgesic according to centre
Specialist
oncology General General
Drug hospitals hospitals practice Total
Controlled release morphine
(MST Continus) 21 (28%) 57 (47%) 38 (68%) 116 (46%)
Morphine elixir 30 (41%) 20 (17%) 1 (2%) 51 (20%)
Diamorphine 12 (16%) 19 (16%) 3 (5%) 34 (14%)
Other strong opioids 3 (4%) 5 (4%) 1 (2%) 9 (4%)
Buprenorphine 2 (3%) 7 (6%) 5 (9%) 14 (6%)
Paracetamol or weak opioids 5 (7%) 6 (5%) 7 (12%) 18 (7%)
Non-steroidal anti-
inflammatory drugs 1 (1%) 6 (5%) 1 (2%) 8 (3%)
(NSAID)
Total 74 (100%) 120 (100%) 56 (100%) 250 (100%)
were chosen by 28% of those qualified for over 20 years
compared with only 8% of those qualified for less than 5
years. Both extent of specialist oncology experience and
seniority also influenced choice of analgesic. A preference for
morphine or diamorphine elixir was related to oncology
experience with 52% of those with more than 3 years
oncology experience choosing these, compared to 24% of
those with no oncology experience. In contrast, MST was
chosen by only 30% of those with more than 3 years
oncology experience but 56% of those with no oncology
experience. The use of weak analgesics was almost exclusively
seen in those with less than I year of oncology experience
(only four doctors with more than 3 years oncology
experience chose weak opioid analgesics).
Two hundred and thirty-one of 248 respondents (93%)
indicated that they would administer their drug offirst choice
regularly, and 17 (7%) 'as required'. Of those who would not
give the drug regularly, only six had chosen morphine as
their drug of first choice, all of these in the form of MST.
The remainder chose buprenorphine (six), an NSAID (two),
weak opioid (two), or 'other opioids' (one).
Two hundred and eight of 248 respondents (84%) chose
the oral route as their first choice route of administration.
Some anomalies between drug of choice and route of choice
were seen: 14 chose parenteral administration, but gave an
oral preparation as their drug of choice (ten MST, and four
an NSAID). Thirteen out of 20 (65%) of those choosing
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Figure 1 Seniority of medical staff in study sample.
intermittent parenteral injections were from the non-specialist
hospitals. Twelve of the 19 who chose a continuous infusion
had previous oncology experience, in contrast to five of the
20 who chose intermittent injections.
The preferred frequency of administration was inevitably
influenced by the drug of first choice. The results for mor-
phine and diamorphine are shown in Table II. Forty-three
(37%) of those who chose MST would administer the drug at
less than 12-hourly intervals and of these 19 would give it
6-hourly or more frequently. This group comprised 15 GP's,
23 general hospital doctors and five doctors in the specialist
oncology hospital. Six respondents (of these 43) indicated
that they would give MST 'as required'.
Thirty-five out of 201 (17%) doctors choosing morphine or
diamorphine defined an upper dose limit, and of these 24 had
chosen MST as their preferred formulation. Twelve of the 35
indicated a limit of less than 100mg, 13 between 100 and
199 mg, and nine greater than 200 mg. One respondent stated
a maximum dose of six MST tablets, strength unspecified. In
contrast, for drugs with a limited therapeutic range (such as
buprenorphine, weak opioids, and NSAIDs) 14 of 40 (35%)
stated that they would use these drugs with no dose limit.
The questionnaire asked respondents to score the relative
importance of five factors influencing drug dosage. Pain
severity emerged as by far the most important determinant of
dose. The remaining four factors were age, body weight,
coexisting chronic lung disease and impaired renal or hepatic
function. No particular preference for any of these four
factors was seen and no clear trends within sub-groups of the
study sample.
Table III shows the action which respondents would take
if their initial treatment resulted in either an inadequate
degree or insufficient duration of analgesia. One hundred and
seventy (68%) indicated that an increase in dose would be
the appropriate action to take for inadequate degree of
analgesia. One hundred and seventy-nine (72%) stated that
in order to resolve inadequate duration of analgesia either
increasing the dose or the frequency of administration was
indicated. Table IV shows the importance respondents placed
Table II Frequency of administration for morphine or diamorphine
(% of those specified)
Morphine or
Frequency diamorphine elixir MST-Continus
2-hourly 4 (5%) 1 (1%)
4-hourly 58 (70%) 13 (11%)
6-hourly 3 (4%) 5 (4%)
8-hourly 1 (1%) 15 (13%)
12-hourly 0 72 (63%)
Other 17 (20%) 9 (8%)
Not specified 0 1
Total 83 (100%) 116 (100%)
'Includes statements such as 'as often as required', 'more often if
necessary', '4-hourly and top-ups' etc.
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Table III Responses to either insufficient duration or degree of
analgesia
Degree ofanalagesia Duration ofanalgesia
Response inadequate inadeqate
Increase dose 170 (68%) 55 (22%)
Increase frequency 9 (4%) 124 (50%)
Give breakthrough 24 (10%) 43 (17%)
medication
Change to regular 6 (2%) 5 (2%)
medication
Change drug to:
(a) one of equivalent 3 (1%) 2 (1%)
strength
(b) stronger drug 30 (12%) 15 (6%)
Other 7 (3%) 5 (2%)
Total 249 (100%) 249 (100%)
Table IV Relative contraindications to the use of strong opioid
analgesics
Response
Contraindication Yes No Possibly Total
Sedation 11 (5%) 145 (59%) 90 (37%) 246
Respiratory 28 (11%) 108 (43%) 113 (45%) 249
depression
Nausea or vomiting 47 (19%) 118 (48%) 82 (33%) 247
Addiction 3 (1%) 237 (96%) 6 (2%) 246
Table V Influence of expected prognosis on use of strong opioid
analgesics
Influence on use ofstrong analgesic
Prognosis Yes No Possibly Total
< I month 2 (1%) 246 (98%) 2 (1%) 250
1-6 months I (1%) 242 (97%) 6 (2%) 249
>6 months 7 (3%) 187 (74%) 58 (23%) 252
upon four recognised side-effects or contra-indications to the
use of strong analgesics in chronic cancer pain. Only three
respondents suggested that the possibility of addiction was a
contraindication to the use of strong opioids. Attitudes
towards recognised side-effects appeared to be consistent
across the groups. Table V shows the influence of prognosis
on the use of strong analgesics. Very few respondents
indicated that an expected prognosis of less than one month
influenced their use of strong opioid analgesics whereas 65
(26%) reported that a prognosis greater than 6 months could
be a deterrent. This figure was made up of 11 (15%) from the
specialist hospital, 18 (32%) of the GPs and 36 (31%) from
the general hospitals.
Discussion
In a previous study, Marks and Sachar sent questionnaires to
physicians in the United States and reported a response rate
of about 70% (Marks & Sachar, 1973). The results reported
here are based on an overall response rate of 42%, with a
range of 34% to 72%. The response was best in the specialist
oncology hospitals (78/116, 67% taking the two together)
where additional follow-up was possible, and where greater
interest in this subject might be expected. This figure is
similar to that obtained by Marks and Sachar. The follow-up
letter in the specialist hospitals in fact prompted only a few
further replies so we feel it unlikely that follow-up of the
non-responders in the other groups would have substantially
improved the overall response rate. There are no comparable
postal questionnaire studies to relate this result to, but
relatively low response rates have been found in other areas,
one recent published example having only a 27% response
rate (Yudkin et al., 1987).
It is important to note that of the 78 respondents in the
specialist hospitals group only six were specifically involved
in pain control, the remainder working in the departments of
medicine, surgery and radiotherapy. Many of these would be
junior staff with no special training in or commitment to a
career in oncology. In this respect their backgrounds and
experience should be similar to the other populations of
hospital doctors surveyed. Thus, whilst it is necessary to
exercise some caution in attempting to extrapolate the results
to the entire study population because of the low response
rate, we believe that the data allow valid inferences to be
drawn. If the specialist hospital data are taken by themselves
they indicate important changes in attitude and knowledge
particularly amongst hospital junior staff. Coupled with the
data from the other groups of doctors sampled the results
give some indications about current practices and also high-
light areas which require further emphasis in teaching on
cancer pain management. Even in these doctors who were
interested and motivated enough to complete the question-
naire there remain some areas of fundamental misunder-
standing.
The guidelines published by the World Health Organis-
ation (WHO, 1986) based on clinical experience in specialist
units in many countries recommend the use of a simple three
step analgesic ladder with morphine as the strong opioid
analgesic of choice given orally on a regular 4-hourly basis.
In this study, 80% of respondents chose morphine (or dia-
morphine) as their first choice analgesic, 84% chose the oral
route, and 87% indicated that they would administer the
analgesic regularly.
Morphine elixir was the formulation of choice in the
specialist oncology hospital, but controlled-release morphine
tablets (MST) were the preferred form in both other hos-
pitals and in general practice and MST was clearly preferred
by those qualified for less than 5 years. Weak opioids or
non-opioids were chosen by a small but significant propor-
tion of doctors (who tended to be in the older age groups).
MST was prescribed in regimens varying from once a day
to every 2 h. This indicates considerable confusion abut
MST. Although awareness of the product is very high, it
appears to be subject to widespread misuse. MST is designed
for 12-hourly administration and rarely has to be given more
frequently (Hanks, 1989). In general, morphine elixir is
preferable for dose titration and whenever the clinical situa-
tion is unstable because of its more rapid onset of action and
shorter duration. MST is much less flexible than the elixir
with peak effects between 2 and 4 h and a duration of 12 h.
The prime indication for MST is maintenance treatment once
patients' morphine requirements have been determined. MST
is particularly inappropriate for 'as required' administration
because of its slow release profile (Poulain et al., 1988).
A well-established principle in the use of morphine for
pain due to advanced cancer is that there is no arbitrary
upper dose limit. A minority of respondents did indicate an
upper dose limit, in many cases at a fairly modest level, and
it is notable that the majority of these doctors used MST as
their preferred formulation. This seems to reflect a generally
less sophisticated knowledge of the effective use of strong
opioid analgesics in these respondents. There was, however,
almost unanimous agreement that the dose chosen should be
primarily determined by the severity of pain.
There were two questions regarding the most appropriate
manoeuvre to be performed ifpain control is inadequate with
the initial choice of drug. Some of these manoeuvres were
dependent upon previous answers, for example a change
from 'as required' administration to regular administration
could only be considered by those first choosing 'as required'
administration. If the degree of pain relief were inadequate,
the majority, as might be expected, chose to increase the
dose. Most others chose either to give breakthrough medica-
tion or change to a stronger analgesic, all of which would be
appropriate. In contrast, where the duration ofanalgesia was
inadequate, half of the respondents chose to increase the
frequency ofadministration, whilst only 22% chose the more
appropriate manoeuvre of increasing the dose.274 I.D. WHITE et al.
Replies regarding the relative contraindications to the use
of strong opioid drugs suggested significant changes in
attitude to that commonly cited, where fear of respiratory
depression and addiction are held to be important reasons
for withholding adequate analgesia (Saunders, 1963; Twy-
cross & Lack, 1983; Marks & Sachar, 1973). In this study
respiratory depression and addiction did not appear to be
seen as major contraindications. Prognosis was not con-
sidered to be a major determining factor in the use of
analgesia, although one quarter of respondents had reserva-
tions about the use of strong opioid analgesics in patients
with a prognosis of more than 6 months.
In conclusion, the majority of respondents in this study
have chosen to use regular morphine or diamorphine given
orally, regularly, titrating the dose to pain severity with no
arbitrary upper limit for severe pain in patients with cancer.
Fears ofrespiratory depression and addiction and a relatively
long prognosis no longer appear to be major deterrents to
the use of strong analgesics in the control of chronic severe
cancer pain.
The data demonstrate that in a specialist oncology hospital
incorporating an active palliative care unit the basic princi-
ples of pain control in advanced cancer can be readily ap-
plied by the majority of doctors. In the more heterogenous
populations of the general hospitals and general practice
problems have been demonstrated even within this group of
motivated responders, particularly in the use of 'as required'
medication by a significant minority and both the choice of
MST as the first choice formulation of morphine and its use
at dose intervals less than 12-hourly. This emphasises the
need for continued efforts in education and research in this
important area to disseminate more widely the accepted prin-
ciples for the management of pain from advanced cancer.
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